mRNA Therapeutics CDMO Market Expected To Reach $8.26 Billion By 2030 As Growth Accelerates At 11.7% CAGR
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
mRNA Therapeutics CDMO Market Forecast: What Market Value Is Expected By 2030?
Over recent years, the market size for mRNA therapeutics CDMOs has experienced rapid expansion, climbing from $4.74 billion in 2025 to $5.31 billion in 2026, reflecting a compound annual growth rate (CAGR) of 12.0%. Historic growth has been driven by several key factors, including the scarce supply of specialized mRNA CDMO offerings, a strong dependence on in-house pharmaceutical production, increasing outbreaks of infectious diseases, the uptake of early-stage analytical testing, and the broadening of academic and research partnerships.
The Mrna Therapeutics Cdmo Market is projected to experience substantial expansion over the coming years. By 2030, its value is anticipated to reach $8.26 billion, reflecting a compound annual growth rate (CAGR) of 11.7%. This forecasted growth is driven by increased investments in Mrna therapeutic pipelines, progress in plasmid DNA and Mrna synthesis techniques, the expansion of cancer immunotherapy and protein replacement therapies, a growing need for fill-finish services, and a rise in collaborative agreements between biotech firms and CDMOs. Emerging trends shaping this period include a heightened demand for outsourced Mrna development and manufacturing, a stronger emphasis on lipid nanoparticle (LNP) formulation methods, the broadening of viral vaccine and cancer immunotherapy pipelines, stricter regulatory compliance and quality control practices, and wider adoption of analytical and bioanalytical laboratory services.
Download A Free Sample Report For Comprehensive Market Insights:
mRNA Therapeutics CDMO Market Growth Drivers: What Factors Are Accelerating Expansion?
The rising prevalence of both chronic and infectious conditions is set to drive expansion in the mRNA therapeutics CDMO market in the coming period. These health issues include long-term ailments like diabetes, heart disease, and asthma, in addition to illnesses triggered by pathogens such as viruses, bacteria, and parasites, which may be transmitted directly or indirectly between people. An increase in these diseases is linked to aging populations, who face a higher risk for both persistent illnesses and infections. By offering comprehensive development and manufacturing solutions that speed up the delivery of customized mRNA treatments to patients, mRNA therapeutics CDMOs play a key role in managing these health challenges. As an example, the World Health Organization, based in Switzerland, reported in October 2024 that around 8.2 million individuals were newly diagnosed with tuberculosis in 2023—up from approximately 7.5 million in 2022—underscoring the worldwide intensification of infectious disease burdens. Consequently, the mounting strain of chronic and infectious illnesses is fueling growth in the mRNA therapeutics CDMO market.
mRNA Therapeutics CDMO Market Segment Landscape: Which Areas Lead Market Development?
The mrna therapeutics cdmo market covered in this report is segmented –
1) By Type Of Service: Development Services, Manufacturing Services, Laboratory Services
2) By Indication: Infectious Diseases, Metabolic And Genetic Diseases, Cardiovascular And Cerebrovascular Diseases
3) By Application: Viral Vaccines, Protein Replacement Therapies, Cancer Immunotherapies
4) By End User: Pharmaceutical Companies, Biotechnology Companies, Academic Institutions, Research Organizations
Subsegments:
1) By Development Services: Process Development, Analytical Method Development, Formulation Development, Regulatory Support
2) By Manufacturing Services: Plasmid DNA Manufacturing, mRNA Synthesis, Lipid Nanoparticle (LNP) Formulation, Fill-Finish Services
3) By Laboratory Services: Quality Control Testing, Stability Testing, Bioanalytical Testing, Preclinical Testing
mRNA Therapeutics CDMO Market Trends: What Is Shaping Future Industry Growth?
Key players in the mRNA therapeutics CDMO market are concentrating on creating advanced solutions like in situ nanomedicine vaccines to improve the accuracy and effectiveness of mRNA-based vaccines via targeted immune activation. An in situ nanomedicine vaccine represents a next-generation mRNA therapy that produces nanomedicines directly within a patient’s body, allowing for precise delivery and customized immune responses through engineered transgene expression. As an illustration, in January 2025, Esphera SynBio Inc., a biotechnology firm based in Canada, began a new project funded by the CQDM Quantum Leap program. This initiative seeks to improve early-stage lipid nanoparticle or messenger RNA (LNP/mRNA) vaccines by integrating proprietary transgene designs that stimulate the in vivo creation of immunostimulatory nanomedicines. Such an approach facilitates accurate antigen delivery and tailored immune responses, marking this technology as a possible major advancement in vaccine development.
mRNA Therapeutics CDMO Market Industry Leaders And Market Competition
Major companies operating in the mrna therapeutics cdmo market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, FUJIFILM Holdings Corporation, Evonik Industries AG, AGC Biologics GmbH, Eurofins Scientific SA, Samsung Biologics Co. Ltd., Wuxi Biologics, Recipharm AB, EMERGENT BioSolutions Inc., Genscript Biotech, Ginkgo Bioworks Holdings Inc., Corden Pharma Corp., TriLink BioTechnologies LLC, Biocina Pty Ltd., Aldevron LLC, Synbio Technologies LLC, etherna manufacturing, Bio-Synthesis Inc., Biomay AG.
Access The Complete mRNA Therapeutics CDMO Market Report:
mRNA Therapeutics CDMO Market Global Footprint: Which Region Holds Market Leadership?
North America was the largest region in the mRNA therapeutics CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mrna therapeutics cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
